Becton Dickinson and Co (BDX) Receives Sector Perform Rating
RBC Capital initiates coverage on Becton Dickinson and Co with a Sector Perform rating.
Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. The company is headquartered in Franklin Lakes, New Jersey and currently employs 74,000 full-time employees. The firm is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for Becton Dickinson and Co.
Last Updated: Dec 11, 2025, 11:08 PM · Source: Finnhub.io
RBC Capital initiates coverage on Becton Dickinson and Co with a Sector Perform rating.
Becton Dickinson and Co (BDX) announces a quarterly dividend of $1.05 per share, reflecting a 1% increase from the previous payout.
Becton Dickinson and Co (BDX) meets Q4 2025 earnings expectations.